# Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

> **NCT02152995** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Metastatic Thyroid Gland Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Thyroid Gland Carcinoma
- Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IV Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7
- Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7
- Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7

## Interventions

- **PROCEDURE:** Computed Tomography
- **OTHER:** Iodine I 124
- **RADIATION:** Iodine I-131
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacodynamic Study
- **PROCEDURE:** Positron Emission Tomography
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02152995
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-08-14
- **Primary completion:** 2021-08-25
- **Final completion:** 2027-02-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152995, "Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02152995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*